Incanthera's (LON:INC) Simon Ward and Tim McCarthy speak to Proactive's Katie Pilbeam about their first full year as a public company on AQSE.
The highlights include discussions with two global cosmetic companies for Sol skin cancer technology which continue to progress.
Their technology portfolio is fully patent protected and was strengthened through the filing of a new patent which gives extended patent protection to Sol to 2040.
And there was £1.14 million of further funding through a recently oversubscribed placing with existing and new investors.